FDA Approved: CARDIZEM LA — Supplemental Application (Bausch Health US LLC)

View source ↗

Summary

FDA's entry shows a supplemental application submission for Cardizem LA (diltiazem hydrochloride extended-release). The sponsor is Bausch Health US LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Atrial Fibrillation
• Atrial Flutter
• Hypertension
• Paroxysmal Supraventricular Tachycardia

Drugs mentioned

• CARDIZEM LA (DILTIAZEM HYDROCHLORIDE)

Snippet

SUPPL AP for CARDIZEM LA (DILTIAZEM HYDROCHLORIDE)